Stripe, Anthropic and OpenAI fund efforts to combat respiratory infections

Stripe, together with AI laboratories Anthropic and OpenAI, have supported a new initiative to prevent respiratory infections — an area where humanity still lacks reliable defenses.

The Problem Everyone Ignores

The common cold is the most widespread infection on the planet. An average adult gets it two to four times a year; a child up to eight times. Despite decades of research, neither a vaccine nor a reliable preventative measure exists. At most, you can take vitamin C and stay away from coughing colleagues. Rhinoviruses, adenoviruses, and coronaviruses constantly mutate — this makes developing universal protection an extremely difficult task. The economic damage from the common cold in the USA is estimated at tens of billions of dollars annually: sick leave, reduced productivity, doctor's visits. The problem was long considered "too minor" for serious investment — this gap has now created a vacuum that private capital is entering.

Who and Why Invest Money

Stripe — the payment company of brothers Patrick and John Collison — announced funding for a new research project in this field. Anthropic and OpenAI joined the initiative: two major players in the AI market that in recent years have increasingly expanded beyond software. Stripe already has experience with unconventional science financing.

Through the Stripe Climate program, the company invested in CO₂ capture technologies when that market was in its infancy. The same logic is being applied to biomedical research: find an unsolved, underfunded problem and support it before it becomes mainstream. For Anthropic and OpenAI, participation in medical projects is part of a strategy to demonstrate the practical value of AI.

Both companies regularly point to the potential of their models in healthcare, and supporting specific research is a way to move from declarations to action.

How AI Changes Medical Research

AI models have already demonstrated value in medicine: AlphaFold predicted the structures of nearly all known proteins; new models accelerate the search for antiviral candidates. In the context of respiratory infections, AI capabilities include:

• Predicting viral mutations and assessing the risk of immune escape
• Analyzing millions of molecular candidates in days instead of years of laboratory screening
• Personalized forecasts — identifying who is at risk for severe disease
• Accelerating clinical trials through synthetic data
• Identifying new drug targets that traditional methods missed

If even some of these capabilities yield results for rhinoviruses, it will change the very logic of antiviral drug development.

What This Means

The emergence of an alliance between Stripe, Anthropic, and OpenAI in medical research is another signal of blurring boundaries between the technology and biomedical sectors. The common cold has remained for decades an inconvenient trifle that no one was rushing to solve seriously. Now resources and tools are being directed at this task that researchers simply did not have before.